BridgeBio prices secondary offering of 5 million shares by KKR Genetic Disorder LP

Reuters2026/08/14 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BridgeBio priced an oversubscribed secondary offering of 5,000,000 common shares sold by KKR Genetic Disorder L.P.
No shares sold by BridgeBio. No proceeds to the company.
Offering expected to close Aug. 17, 2026, subject to customary closing conditions.
William Blair, Goldman Sachs, KKR Capital Markets acting as joint book-running managers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140730PRIMZONEFULLFEED9810176) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BridgeBio prices secondary offering of 5 million shares by KKR Genetic Disorder LP

You may also like

Crypto prices